Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriers

12 Apr 2019

Abstract excerpt

Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate, which acts as an oncometabolite. Germline SDHx mutations predispose to paraganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and gastro-intestinal stromal tumors. The SDHx genes were the first tumor suppressor genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto Warburg's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal and Paraganglionic Tumors
Share to Cancer, Hypoxia, and Metabolism
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30977114
DOI: 10.1111/cge.13553

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriersPMID 30977114Read ↗

Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.Semantic proximity Read ↗

Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.Semantic proximity Read ↗

Metabolic Effects of Succinate Dehydrogenase Loss in CancerSemantic proximity Read ↗

The Emerging Role of Succinate Dehyrogenase Genes (SDHx) in TumorigenesisSemantic proximity Read ↗

Epigenetic and metabolic reprogramming of SDH-deficient paragangliomasSemantic proximity Read ↗

Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors.Semantic proximity Read ↗

Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.Semantic proximity Read ↗

A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma.Semantic proximity Read ↗

Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriersSemantic proximity Read ↗

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas.Semantic proximity Read ↗

Succinate Dehydrogenase Complex: An Updated ReviewSemantic proximity Read ↗

A study of succinate dehydrogenase deficient tumourigenesis : from functional assessment of variant pathogenicity to the discovery of new disease biomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.